141 results on '"Mäkitie, Antti"'
Search Results
2. Psychosocial factors and patient and healthcare delays in large (class T3–T4) oral, oropharyngeal, and laryngeal carcinomas
- Author
-
Atula, Markus, Atula, Timo, Aro, Katri, Irjala, Heikki, Halme, Elina, Jouppila-Mättö, Anna, Koivunen, Petri, Wilkman, Tommy, Mäkitie, Antti, Elovainio, Marko, and Pulkki-Råback, Laura
- Published
- 2024
- Full Text
- View/download PDF
3. Enhanced recovery after surgery (ERAS) protocol improves patient outcomes in free flap surgery for head and neck cancer
- Author
-
Nieminen, Teija, Tapiovaara, Laura, Bäck, Leif, Lindford, Andrew, Lassus, Patrik, Lehtonen, Lasse, Mäkitie, Antti, and Keski-Säntti, Harri
- Published
- 2024
- Full Text
- View/download PDF
4. Occupational variation in incidence of oropharyngeal cancer in the Nordic countries
- Author
-
Nikkilä, Rayan, Mäkitie, Antti, Carpén, Timo, Hansen, Johnni, Heikkinen, Sanna, Lynge, Elsebeth, Selander, Jenny, Mehlum, Ingrid Sivesind, Torfadottir, Jóhanna Eyrún, Salo, Tuula, and Pukkala, Eero
- Published
- 2024
- Full Text
- View/download PDF
5. A Meta-analysis of Surgical Outcomes of T4a and Infranotch T4b Oral Cancers
- Author
-
Rao, Karthik Nagaraja, Arora, Ripudaman, Dange, Prajwal, Nagarkar, Nitin, Mäkitie, Antti A., Kowalski, Luiz P., Eisbruch, Avraham, Hamoir, Marc, Civantos, Francisco J., Vander Poorten, Vincent, Ng, Sweet Ping, Nuyts, Sandra, Zafereo, Mark, Asarkar, Ameya A., Golusinski, Paweł, Ronen, Ohad, and Ferlito, Alfio
- Published
- 2023
- Full Text
- View/download PDF
6. Costs of oropharyngeal squamous cell cancer treatment in Finland
- Author
-
Tikkanen, Juhana, Nieminen, Teija, Lassus, Patrik, Tenhunen, Mikko, Lehtonen, Lasse, and Mäkitie, Antti
- Published
- 2023
- Full Text
- View/download PDF
7. The risk of second primary cancer after nasopharyngeal cancer: a systematic review
- Author
-
Svärd, Fanni, Alabi, Rasheed Omobolaji, Leivo, Ilmo, Mäkitie, Antti A., and Almangush, Alhadi
- Published
- 2023
- Full Text
- View/download PDF
8. Artificial Intelligence in Head and Neck Cancer: A Systematic Review of Systematic Reviews
- Author
-
Mäkitie, Antti A., Alabi, Rasheed Omobolaji, Ng, Sweet Ping, Takes, Robert P., Robbins, K. Thomas, Ronen, Ohad, Shaha, Ashok R., Bradley, Patrick J., Saba, Nabil F., Nuyts, Sandra, Triantafyllou, Asterios, Piazza, Cesare, Rinaldo, Alessandra, and Ferlito, Alfio
- Published
- 2023
- Full Text
- View/download PDF
9. Management of Older Patients with Head and Neck Cancer: A Comprehensive Review
- Author
-
Matos, Leandro L., Sanabria, Alvaro, Robbins, K. Thomas, Halmos, Gyorgy B., Strojan, Primož, Ng, Wai Tong, Takes, Robert P., Angelos, Peter, Piazza, Cesare, de Bree, Remco, Ronen, Ohad, Guntinas-Lichius, Orlando, Eisbruch, Avraham, Zafereo, Mark, Mäkitie, Antti A., Shaha, Ashok R., Coca-Pelaz, Andres, Rinaldo, Alessandra, Saba, Nabil F., Cohen, Oded, Lopez, Fernando, Rodrigo, Juan P., Silver, Carl E., Strandberg, Timo E., Kowalski, Luiz Paulo, and Ferlito, Alfio
- Published
- 2023
- Full Text
- View/download PDF
10. Hypopharyngeal carcinoma in Finland from 2005 to 2014: outcome remains poor after major changes in treatment
- Author
-
Keski-Säntti, Harri, Luukkaa, Marjaana, Carpén, Timo, Jouppila-Mättö, Anna, Lehtiö, Kaisa, Mäenpää, Hanna, Vuolukka, Kristiina, Vahlberg, Tero, and Mäkitie, Antti
- Published
- 2023
- Full Text
- View/download PDF
11. Managing Cachexia in Head and Neck Cancer: a Systematic Scoping Review
- Author
-
Mäkitie, Antti A., Alabi, Rasheed Omobolaji, Orell, Helena, Youssef, Omar, Almangush, Alhadi, Homma, Akihiro, Takes, Robert P., López, Fernando, de Bree, Remco, Rodrigo, Juan P., and Ferlito, Alfio
- Published
- 2022
- Full Text
- View/download PDF
12. Socio-economic status and head and neck cancer incidence in the Nordic countries.
- Author
-
Nikkilä, Rayan, Carpén, Timo, Hansen, Johnni, Heikkinen, Sanna, Lynge, Elsebeth, Martinsen, Jan Ivar, Selander, Jenny, Mehlum, Ingrid Sivesind, Torfadóttir, Jóhanna Eyrún, Mäkitie, Antti, and Pukkala, Eero
- Subjects
HEAD & neck cancer ,TONGUE cancer ,LARYNGEAL cancer ,SOCIOECONOMIC status ,OROPHARYNGEAL cancer - Abstract
Background The impact of societal factors on the occurrence of head and neck cancers (HNCs) remains understudied, especially in the Nordic countries. Methods To quantify the association between socio-economic status (SES) and the occurrence of HNCs, this cohort study uses data from the Nordic Occupational Cancer project that combine occupational and cancer registry data from 1961 to 2005 of 14.9 million individuals aged between 30 and 64 years. Occupational categories were combined into seven socio-economic categories. Standardized incidence ratio (SIR) analyses were conducted with the cancer incidence rates for the entire national study populations used as reference rates. Results Altogether, 83 997 HNCs—72% in men and 28% in women—were recorded. Among men, a gradient of risk associated with SES was observed for cancers of the tongue, other oral cavity subsites, pharynx, oropharynx and larynx in groups with lower SES. Managers showed decreased SIRs of 0.50 to –0.90 also for cancers of the lip, tongue, other oral cavity subsites, oropharynx, nasopharynx, nose and larynx. In contrast, excess risks of tongue, other oral cavity subsites, pharyngeal, oropharyngeal and laryngeal cancers were observed among clerical (SIRs 1.05–1.16), skilled workers (1.04–1.14), unskilled workers (1.16–1.26) and economically inactive men (1.38–1.87). Among women, no risk gradient similar to that in men was revealed. Conclusions The current study underscores the influence of SES on the incidence of HNCs and highlights the need for targeted interventions, including tobacco and alcohol control policies, and improved access to healthcare services, particularly for socio-economically disadvantaged populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Standardization for oncologic head and neck surgery
- Author
-
Ronen, Ohad, Robbins, K. Thomas, de Bree, Remco, Guntinas-Lichius, Orlando, Hartl, Dana M., Homma, Akihiro, Khafif, Avi, Kowalski, Luiz P., López, Fernando, Mäkitie, Antti A., Ng, Wai Tong, Rinaldo, Alessandra, Rodrigo, Juan P., Sanabria, Alvaro, and Ferlito, Alfio
- Published
- 2021
- Full Text
- View/download PDF
14. Enteral tube feeding of head and neck cancer patients undergoing definitive chemoradiotherapy in the Nordic Countries: Survey of the Scandinavian Society for Head and Neck Oncology
- Author
-
Ilmarinen, Taru, Hammarstedt-Nordenvall, Lalle, Bäck, Leif, and Mäkitie, Antti
- Published
- 2021
- Full Text
- View/download PDF
15. A Nordic survey of the management of palliative care in patients with head and neck cancer
- Author
-
Boëthius, Helena, Saarto, Tiina, Laurell, Göran, Farnebo, Lovisa, and Mäkitie, Antti A.
- Published
- 2021
- Full Text
- View/download PDF
16. Stereotactic Body Radiotherapy in Recurrent and Oligometastatic Head and Neck Tumours.
- Author
-
Tham, Jodie L. M., Ng, Sweet Ping, Khor, Richard, Wada, Morikatsu, Gan, Hui, Thai, Alesha A., Corry, June, Bahig, Houda, Mäkitie, Antti A., Nuyts, Sandra, De Bree, Remco, Strojan, Primož, Ng, Wai Tong, Eisbruch, Avraham, Chow, James C. H., and Ferlito, Alfio
- Subjects
STEREOTACTIC radiotherapy ,RADIOTHERAPY ,HEAD & neck cancer ,TREATMENT failure ,NECK ,TUMORS - Abstract
The treatment of head and neck cancers (HNCs) encompasses a complex paradigm involving a combination of surgery, radiotherapy, and systemic treatment. Locoregional recurrence is a common cause of treatment failure, and few patients are suitable for salvage surgery. Reirradiation with conventional radiation techniques is challenging due to normal tissue tolerance limits and the risk of significant toxicities. Stereotactic body radiotherapy (SBRT) has emerged as a highly conformal modality that offers the potential for cure while limiting the dose to surrounding tissue. There is also growing research that shows that those with oligometastatic disease can benefit from curative intent local ablative therapies such as SBRT. This review will look at published evidence regarding the use of SBRT in locoregional recurrent and oligometastatic HNCs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Stereotactic Body Radiotherapy as a Curative Treatment for De Novo Mucosal Carcinoma of the Head and Neck: A Feasible Alternative Option for Fragile Patients with Small Lesion: A Systematic Review †.
- Author
-
Strojan, Primož, Kokalj, Marko, Plavc, Gaber, Ng, Sweet Ping, Nuyts, Sandra, Chiesa-Estomba, Carlos M., Eisbruch, Avraham, de Bree, Remco, Chow, James C. H., Mäkitie, Antti A., Lopez, Fernando, Saba, Nabil F., and Ferlito, Alfio
- Subjects
HEAD & neck cancer diagnosis ,SQUAMOUS cell carcinoma ,DRUG toxicity ,PATIENT safety ,PROFESSIONAL practice ,RESEARCH funding ,HEAD & neck cancer ,RADIOSURGERY ,DESCRIPTIVE statistics ,TREATMENT effectiveness ,EXPERIENCE ,SYSTEMATIC reviews ,MEDLINE ,QUALITY of life ,COMBINED modality therapy ,RADIATION doses ,ONLINE information services - Abstract
Simple Summary: Stereotactic body radiotherapy (SBRT) is a highly precise, non-invasive, and image-guided form of hypofractionated radiotherapy aimed at well-defined small targets. It is characterized by superior conformity of dose distribution, steep dose drop-off gradients, and short overall treatment time, which allow effective protection of surrounding normal tissue from high radiation doses, potentially resulting in lower toxicity and a more potent biological effect. Currently, SBRT is an established curative therapy for certain cancers and some benign tumors, as well as a valuable palliative option. There is limited experience with SBRT for de novo mucosal carcinoma of the head and neck. A systematic review of the literature and subsequent analysis of 124 patients from five studies treated between 2012 and 2020 confirmed that SBRT is an effective and relatively safe treatment for small tumor targets in de novo mucosal carcinoma of the head and neck. Standardization of SBRT practice and well-designed prospective clinical trials are highly needed. Stereotactic body radiotherapy (SBRT) is characterized by a high dose per fraction, well-defined small targets, superior dose conformity, and a steep off-target dose gradient. A literature search was conducted to examine the experience with SBRT as a curative treatment for newly diagnosed mucosal carcinoma of the head and neck (MCHN). Four retrospective case series and one prospective phase I clinical trial published between 2012 and 2020 described 124 patients. SBRT was mainly performed in older patients with different tumor sites. The median size of the planning target volumes ranged from 5.3 to 41 cm
3 . Different approaches were used to create margins. In two studies, limited elective nodal irradiation was performed. The equivalent doses used were 60–83.33 Gy delivered in five fractions. Considerable heterogeneity was observed in the radiation dose specification. The incidence of grade ≥3 late toxicity was 0–8.3%, with local and regional control ranging from 73% to 100%. Improved or stable quality of life after SBRT was reported in two studies. Curative-intent SBRT for de novo MCHN appears to be an effective and relatively safe treatment for small tumor targets, preferably without concomitant elective tissue irradiation. Standardization of SBRT practice and well-designed prospective clinical trials are needed to better define the role of SBRT in this setting. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
18. Pretreatment fat‐free mass index correlates with early death in patients with head and neck squamous cell carcinoma.
- Author
-
Talani, Charbél, Astradsson, Thorsteinn, Farnebo, Lovisa, Mäkitie, Antti, Ehrsson, Ylva Tiblom, and Laurell, Göran
- Subjects
SQUAMOUS cell carcinoma ,EARLY death ,HEAD & neck cancer ,TERMINATION of treatment ,BODY mass index ,BIOELECTRIC impedance - Abstract
Background: A significant proportion of patients with head and neck squamous cell carcinoma (HNSCC) are malnourished at diagnosis. In this study, we investigated how pretreatment body mass index (BMI) and fat‐free mass index (FFMI) correlate with early death, and whether these measurements are useful markers of prognosis for risk stratification of head and neck cancer patients. Methods: Patients (n = 404) with newly diagnosed, curable HNSCC and WHO performance status 0–2 were prospectively included and met with a study representative before treatment initiation, as well as up to four follow‐up visits. All patients provided an estimate of body weight at 6 months prior to diagnosis. Bioelectrical impedance analysis (BIA) was performed for all patients before treatment initiation. Results: Most patients had oropharyngeal (46%), oral cavity (28%), or laryngeal cancer (12%). Forty‐five (11%) patients met the standardized criteria for malnutrition according to the Global Leadership Initiative on Malnutrition (GLIM) at diagnosis. FFMI at diagnosis was lower in patients who died within 6 and 12 months after the start of treatment than in patients who survived these time points (p = 0.035 and p = 0.005, respectively). Conclusions: In this study, pretreatment FFMI was an independent prognostic factor for death within 6 and 12 months after the start of treatment in patients with HNSCC. Pretreatment BMI was not an independent risk factor for death within 6 and 12 months after treatment termination. Thus, FFMI may be useful for risk stratification of patients with head and neck cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Body composition changes in patients with head and neck cancer under active treatment: a scoping review
- Author
-
Ferrão, Bárbara, Neves, Pedro Miguel, Santos, Teresa, Capelas, Manuel Luís, Mäkitie, Antti, and Ravasco, Paula
- Published
- 2020
- Full Text
- View/download PDF
20. Clinical significance of tumor-stroma ratio in head and neck cancer: a systematic review and meta-analysis
- Author
-
Almangush, Alhadi, Alabi, Rasheed Omobolaji, Troiano, Giuseppe, Coletta, Ricardo D., Salo, Tuula, Pirinen, Matti, Mäkitie, Antti A., and Leivo, Ilmo
- Published
- 2021
- Full Text
- View/download PDF
21. Induction of Collagenolytic MMP-8 and -9 Tissue Destruction Cascade in Mouth by Head and Neck Cancer Radiotherapy: A Cohort Study.
- Author
-
Brandt, Ella, Keskin, Mutlu, Räisänen, Ismo T., Tervahartiala, Taina, Mäkitie, Antti, Harmankaya, İlknur, Karaçetin, Didem, Hagström, Jaana, Rautava, Jaana, and Sorsa, Timo
- Subjects
MATRIX metalloproteinases ,HEAD & neck cancer ,CANCER radiotherapy ,GINGIVAL hemorrhage ,COHORT analysis - Abstract
The effect of head and neck cancer (HNC) radiotherapy (RT) on biomarkers is not known but there is a lot of potential for gaining more precise cancer treatments and less side effects. This cohort study investigated the levels and molecular forms of the matrix metalloproteinase (MMP) -8 and -9, tissue inhibitor of metalloproteinase (TIMP)-1, myeloperoxidase (MPO) and interleukin (IL)-6 in mouth-rinse samples as well as the clinical periodontal status in HNC patients (n = 21) receiving RT. Complete periodontal examinations were performed pre-RT and one month after RT. Mouth-rinse samples (pre-RT, after six weeks of RT and one month after RT) were assayed using a point-of-care-kit (PerioSafe
® /ORALyzer® (Dentognostics GmbH, Jena, Germany)) for active MMP-8 and ELISA analysis for total MMP-8 and -9, MPO, TIMP-1, and IL-6 levels. Molecular forms of MMP-9 were assessed by gelatinolytic zymography and MMP-8 by western immunoblot. Significant changes were observed between the three time points in the mean levels of active and total MMP-8, active MMP-9, and IL-6. Their levels increased during the RT and decreased after the RT period. The aMMP-8 levels stayed elevated even one month after RT compared to the pre-RT. Clinical attachment loss, probing depths, and bleeding on probing were increased between pre- and post-calculations in periodontal status. Elevated inflammatory biomarker levels together with clinical recordings strongly suggest that RT eventually increases the risk to the periodontal tissue destruction by inducing the active proteolytical MMP-cascade, and especially by prolonged activity of collagenolytic aMMP-8. Eventually, the aMMP-8 point-of-care mouth-rinse test could be an easy, early detection tool for estimating the risk for periodontal damage by the destructive MMP-cascade in HNC patients with RT treatment. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
22. Management of clinically N0 neck in oropharyngeal carcinoma
- Author
-
Jouhi, Lauri, Atula, Timo, Mäkitie, Antti, and Keski-Säntti, Harri
- Published
- 2019
- Full Text
- View/download PDF
23. Newly detected DNA viruses in juvenile nasopharyngeal angiofibroma (JNA) and oral and oropharyngeal squamous cell carcinoma (OSCC/OPSCC)
- Author
-
Dickinson, Amy, Xu, Man, Silén, Suvi, Wang, Yilin, Fu, Yu, Sadeghi, Mohammadreza, Toppinen, Mari, Carpén, Timo, Hedman, Klaus, Mäkitie, Antti, and Söderlund-Venermo, Maria
- Published
- 2019
- Full Text
- View/download PDF
24. Iron, Ferroptosis, and Head and Neck Cancer.
- Author
-
Teng, Yong, Gao, Lixia, Mäkitie, Antti A., Florek, Ewa, Czarnywojtek, Agata, Saba, Nabil F., and Ferlito, Alfio
- Subjects
HEAD & neck cancer ,REACTIVE oxygen species ,IRON ,THERAPEUTICS ,CELL death ,DRUG resistance ,CANCER treatment - Abstract
Ferroptosis is an iron-dependent regulatory form of cell death characterized by the accumulation of intracellular reactive oxygen species and lipid peroxidation. It plays a critical role not only in promoting drug resistance in tumors, but also in shaping therapeutic approaches for various malignancies. This review aims to elucidate the relationship between ferroptosis and head and neck cancer treatment by discussing its conceptual framework, mechanism of action, functional aspects, and implications for tumor therapy. In addition, this review consolidates strategies aimed at improving the efficacy of head and neck cancer treatment through modulation of ferroptosis, herein serving as a valuable reference for advancing the treatment landscape for this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Review of Outcomes after Salvage Surgery for Recurrent Squamous Cell Carcinoma of the Head and Neck.
- Author
-
Hartl, Dana M., Guerlain, Joanne, Gorphe, Philippe, Kapre, Madan, Kapre Gupta, Neeti, Saba, Nabil F., Robbins, K. Thomas, Ronen, Ohad, Rodrigo, Juan P., Strojan, Primož, Mäkitie, Antti A., Kowalski, Luiz P., Shah, Jatin P., and Ferlito, Alfio
- Subjects
HEAD & neck cancer treatment ,ADJUVANT chemotherapy ,HEAD & neck cancer ,TREATMENT effectiveness ,CHEMORADIOTHERAPY ,DISEASE relapse ,HEALTH literacy ,SALVAGE therapy ,SQUAMOUS cell carcinoma - Abstract
Simple Summary: Local recurrences, isolated regional recurrences, and loco-regional recurrences are frequent after treatment for advanced stage head and neck squamous cell carcinoma. Salvage surgery may be possible in selected patients, taking into account the location and stage of the recurrent disease, patient age and comorbidities, tumor HPV status, and functional sequelae in relation to initial therapy. Results vary according to these parameters. Adjuvant treatments after salvage surgery are under investigation. The aim of this review is to present current knowledge concerning the incidence and management of recurrent head and neck squamous cell carcinoma and current data concerning survival and morbidity after salvage surgery. Surgery with adjuvant chemoradiotherapy or chemoradiotherapy is the mainstay in treatment for advanced stage head and neck squamous cell carcinoma; however, locoregional recurrences are frequent. Salvage surgery could be proposed in selected patients to improve local control, disease-free, and overall survival. Factors for improved disease-free and overall survival in patients treated with salvage surgery include age, tumor location, the initial T stage, HPV status, resection margins, and the time elapsing from the initial treatment. Clinical trials with adjuvant therapies have shown promise after salvage surgery in terms of tolerance and response, but clinical guidelines for using these adjuvant treatments are currently lacking. The aim of this review is to present current knowledge concerning the incidence and management of recurrent head and neck squamous cell carcinoma and current data concerning survival and morbidity after salvage surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Significant risk of second primary cancer among laryngeal squamous cell carcinoma patients even after 20 years.
- Author
-
Nikkilä, Rayan, Hirvonen, Elli, Haapaniemi, Aaro, Tapiovaara, Laura, Pitkäniemi, Janne, Malila, Nea, and Mäkitie, Antti
- Subjects
CANCER patient psychology ,LIFESTYLES ,CONFIDENCE intervals ,SMOKING cessation ,LARYNGEAL tumors ,RISK assessment ,SECONDARY primary cancer ,DESCRIPTIVE statistics ,RESEARCH funding ,SQUAMOUS cell carcinoma ,AGE groups ,DISEASE risk factors - Abstract
Background: Evidence on the risk of second primary cancer (SPC) following primary laryngeal squamous cell carcinoma (LSCC) is limited, especially in Europe. Methods: Patients diagnosed with primary LSCC from 1953-2018 were retrieved from the Finnish Cancer Registry. A total of 6241 LSCC patients were identified adding to 49,393 person-years (PY) of follow-up until the end of 2019. Only one patient emigrated and was lost to follow-up. Both standardized incidence ratios (SIR) and excess absolute risk (EAR) per 1000 person-years at risk (PYR) of second primary cancer (SPC) were calculated relative to the general population. Only non-laryngeal SPCs diagnosed six months after diagnosis of primary LSCC were included. Results: A SPC was diagnosed in 1244 LSCC patients (20% of all LSCC patients) over the 65-year period, predominantly in men (92%, n=1170). Out of all SPCs, 34% were diagnosed within 0.5 to 5 years and 66% after 5 years from primary LSCC. Among male patients, the overall SIR for SPC at any location was 1.61 (95% CI: 1.52-1.71), corresponding to 9.49 excess SPCs per 1000 PYR (95% CI: 8.19-11). The corresponding SIR for women was 1.47 (95% CI: 1.15-1.84), yielding 4.82 excess SPCs per 1000 PYR (95% CI: 2.36-9.84). The risk remained significant even after 20 years of follow-up (SIR for all 1.73, 95% CI: 1.49-2.01 and EAR 16.8 per 1000 PY, 11.88-23.75). The risk for SPC was also significantly elevated in all age groups, except <40. The highest SIRs were for SPCs arising in the mouth/pharynx (SIR for all 3.08, 95% CI: 2.36-3.95 and EAR 0.80 per 1000 PY, 0.55-1.15) and lungs (3.02, 2.75-3.30 and 5.90 per 1000, 5.13-6.78). Conclusion: Patients with LSCC as primary cancer have a 60% excess risk for an SPC, especially for tobacco-associated cancers, remaining significantly elevated even decades after treatment. NOVELTY & IMPACT Although prior research on the risk of second primary cancer (SPC) among laryngeal squamous cell carcinoma (LSCC) patients has been conducted in other regions, the European perspective remains notably underrepresented. Moreover, studies on the subject focusing especially on LSCC are, even globally, only a few. The present study, with over 6000 LSCC patients followed-up over six decades, consists of the largest reported cohort of LSCC patients in Europe, and with the longest follow-up. Patients with LSCC as a primary cancer have a 60% excess risk for an SPC, which remains significantly elevated even 20 years after the diagnosis of the first primary cancer, especially for those with a tobacco/alcohol-related cancer. Healthcare professionals should be aware of the SPC risk among LSCC survivors who should be counseled about this phenomenon. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Survival Outcomes in T3 Laryngeal Cancers: Primary Total Laryngectomy vs. Concurrent Chemoradiation or Radiation Therapy—A Meta-Analysis †.
- Author
-
Rao, Karthik Nagaraja, Pai, Prathamesh S., Dange, Prajwal, Kowalski, Luiz P., Strojan, Primož, Mäkitie, Antti A., Guntinas-Lichius, Orlando, Robbins, K. Thomas, Rodrigo, Juan P., Eisbruch, Avraham, Takes, Robert P., de Bree, Remco, Coca-Pelaz, Andrés, Piazza, Cesare, Chiesa-Estomba, Carlos, López, Fernando, Saba, Nabil F., Rinaldo, Alessandra, and Ferlito, Alfio
- Subjects
LARYNGECTOMY ,LARYNGEAL cancer ,RADIOTHERAPY ,SURVIVAL rate ,CHEMORADIOTHERAPY ,HEAD & neck cancer - Abstract
Background: The management of cT3 laryngeal cancers remains controversial, with studies recommending surgical or non-surgical approaches. Despite the many papers that have been published on the subject, there is a lack of studies showing which treatment has better results in terms of survival. Objective: To determine the difference in survival outcomes following total laryngectomy (TL), concurrent chemoradiation (CRT) or radiation therapy (RT) alone in T3 laryngeal cancers. Methods: Search of PubMed, Scopus, and Google Scholar databases from 1995 to 2023 employing specific keywords and Boolean operators to retrieve relevant articles. Statistical analysis was conducted using a random-effects model, and heterogeneity was evaluated using the Q-test and I
2 statistic. Funnel plot asymmetry was assessed using rank correlation and regression tests. Results: The qualitative data synthesis comprised 10,940 patients from 16 included studies. TL was performed in 2149 (19.4%), CRT in 6723 (61.5%), RT in 295 (2.7%), while non-surgical treatment was not specified in 1773 (16.2%) patients. The pooled 2-year overall survival (OS) rates were TL = 73%, CRT = 74.7%, RT = 57.9%, 3-year OS rates were TL = 64.3%, CRT = 62.9%, RT = 52.4%, and 5-year OS rates were TL = 54.2%, CRT = 52.7%, RT = 40.8%. There was a significant heterogeneity in the included studies. There was no statistically significant difference in 2-year OS (logOR= −0.88 (95% confidence interval (CI): −1.99 to 0.23), p = 0.12), 3-year OS (logOR = −0.6 (95% CI: −1.34 to 0.15), p = 0.11), and 5-year OS (logOR = −0.54 (95% CI: −1.29 to 0.21), p = 0.16) between TL and CRT. Instead, there was significant difference in 2-year OS (logOR= −1.2383 (95% CI: −2.1679 to −0.3087), p = 0.009), 3-year OS (−1.1262 (95% CI: −1.6166 to −0.6358), p < 0.001), and 5-year OS (−0.99 (95% CI: −1.44 to −0.53)), p < 0.001) between TL and RT alone. Conclusions and Significance: TL followed with adjuvant (chemo)radiation on indication and CRT with salvage surgery in reserve appear to have similar OS outcomes. Both resulted in better OS outcomes compared to RT alone in the treatment of T3 laryngeal cancers. If patients are unfit for chemotherapy, making CRT impossible, surgery may become the choice of treatment. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
28. Prospective experience of percutaneous endoscopic gastrostomy tubes placed by otorhinolaryngologist—head and neck surgeons: safe and efficacious
- Author
-
Ruohoalho, Johanna, Aro, Katri, Mäkitie, Antti A., Atula, Timo, Haapaniemi, Aaro, Keski-Säntti, Harri, Kylänpää, Leena, Takala, Annika, and Bäck, Leif J.
- Published
- 2017
- Full Text
- View/download PDF
29. Toll-like receptor 5 and 7 expression may impact prognosis of HPV-positive oropharyngeal squamous cell carcinoma patients
- Author
-
Jouhi, Lauri, Mohamed, Hesham, Mäkitie, Antti, Remes, Satu Maria, Haglund, Caj, Atula, Timo, and Hagström, Jaana
- Published
- 2017
- Full Text
- View/download PDF
30. Occupational variation in the incidence of lip cancer in the Nordic countries.
- Author
-
Mroueh, Rayan, Carpén, Timo, Mäkitie, Antti, Hansen, Johnni, Heikkinen, Sanna, Lynge, Elsebeth, Martinsen, Jan Ivar, Selander, Jenny, Mehlum, Ingrid Sivesind, Torfadottir, Jóhanna Eyrún, Salo, Tuula, and Pukkala, Eero
- Subjects
OCCUPATIONAL diseases ,DATABASES ,CONFIDENCE intervals ,OCCUPATIONAL exposure ,LIP tumors ,HEAD & neck cancer ,RISK assessment ,OCCUPATIONS ,RESEARCH funding ,SCANDINAVIANS ,NORDIC people ,DISEASE risk factors - Abstract
While certain occupations, such as agriculture and fishery, have been associated with an increased risk of lip cancer, the occupational risk profile of lip cancer and its change over time remain poorly known. This study aims to evaluate the incidence of lip cancer across different occupations in the Nordic countries. The Nordic Occupational Cancer Study (NOCCA) covers 14.9 million people and includes 45 years of cancer incidence data, from 1961 to 2005, linked to occupational categories for all the five Nordic populations. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were used to quantify the risk of lip cancer across occupational categories relative to the entire national populations. There were a total of 14,477 male and 3008 female lip cancer patients identified during follow up. The highest SIRs were observed among male fishermen (SIR 2.26, 95% CI: 2.04–2.50), gardeners (SIR 1.60, 95% CI: 1.48–1.72), and farmers (SIR 1.60, 95% CI: 1.55–1.66). A significantly reduced risk of lip cancer (SIR < 0.50) was observed among male physicians, teachers, religious workers, artistic workers, journalists, administrators, printers, waiters, and hairdressers. Among women, no occupations were associated with an increased risk of lip cancer. The incidence of lip cancer varies widely between outdoor and indoor occupations. Occupations involving outdoor activity and exposure to sunlight show the most elevated SIRs. Certain outdoor occupations, such as agriculture and fishery, have been associated with an increased risk of lip cancer. However, the occupational risk profile of lip cancer and its change over time remain poorly known. This study highlights the excess risk of lip cancer among men with outdoor occupations and further corroborates previous studies. Efforts to counsel outdoor workers on the risk and prevention of lip cancer are needed to reduce the societal burden of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Treatment and outcome among patients with laryngeal squamous cell carcinoma in Stockholm—A population‐based study.
- Author
-
Blomkvist, Rasmus, Marklund, Linda, Hammarstedt‐Nordenvall, Lalle, Gottlieb‐Vedi, Eivind, Mäkitie, Antti, and Palmgren, Björn
- Subjects
SQUAMOUS cell carcinoma ,OVERALL survival ,HEAD & neck cancer - Abstract
Objective: Survival of patients with advanced laryngeal squamous cell carcinoma (LSCC) remains poor and management protocols warrant further development. We thus investigated treatment and outcome‐related factors for LSCC in Stockholm, Sweden. Methods: In a retrospective setting, 520 patients with LSCC diagnosed during 2000–2014, were included. Data on stage, treatment, and outcome were correlated with recurrence‐free and overall survival (RFS and OS, respectively). Results: Five‐year OS for all patients was 65%. Five‐year RFS for T1a, T1b, T2, T3, and T4 glottic LSCC was 90%, 91%, 77%, 47%, and 80%, respectively. The corresponding figures for T1, T2, T3, and T4 supraglottic LSCC were 64%, 66%, 64%, and 86%. Conclusion: Patients with a T3 glottic LSCC had unexpectedly poor survival, especially when compared with patients with a T4 tumor. Patients with T4 disease were primarily treated with laryngectomy and postoperative radiotherapy (RT)/chemoradiotherapy (CRT), while most patients with T3 LSCC were treated with RT/CRT. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Trends in the 15D health-related quality of life over the first year following diagnosis of head and neck cancer
- Author
-
Aro, K., Bäck, L., Loimu, V., Saarilahti, K., Rogers, S., Sintonen, H., Roine, R., and Mäkitie, Antti
- Published
- 2016
- Full Text
- View/download PDF
33. Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma—an in vivo and in vitro study
- Author
-
Jouhi, Lauri, Datta, Neeta, Renkonen, Suvi, Atula, Timo, Mäkitie, Antti, Haglund, Caj, Ahmed, Abdirisak, Syrjänen, Stina, Grénman, Reidar, Auvinen, Eeva, Lehtonen, Sanna, and Hagström, Jaana
- Published
- 2015
- Full Text
- View/download PDF
34. miR-22 and miR-205 Drive Tumor Aggressiveness of Mucoepidermoid Carcinomas of Salivary Glands
- Author
-
Naakka, Erika, Barros-Filho, Mateus Camargo, Adnan-Awad, Shady, Al-Samadi, Ahmed, Marchi, Fábio Albuquerque, Kuasne, Hellen, Korelin, Katja, Suleymanova, Ilida, Brown, Amy Louise, Scapulatempo-Neto, Cristovam, Lourenço, Silvia Vanessa, Castilho, Rogério Moraes, Kowalski, Luiz Paulo, Mäkitie, Antti, Araújo, Vera Cavalcanti, Leivo, Ilmo, Rogatto, Silvia Regina, Salo, Tuula, Passador-Santos, Fabricio, Department of Oral and Maxillofacial Diseases, TRIMM - Translational Immunology Research Program, HUS Head and Neck Center, HUSLAB, CAN-PRO - Translational Cancer Medicine Program, Clinicum, Korva-, nenä- ja kurkkutautien klinikka, Research Program in Systems Oncology, Institute of Biomedicine (-2014), Department of Pathology, and Helsinki University Hospital Area
- Subjects
INVOLVEMENT ,EXPRESSION ,microRNA ,MICRORNAS ,3122 Cancers ,REARRANGEMENT ,salivary gland tumor ,oral cancer ,ELECTIVE NECK DISSECTION ,TRANSLOCATION ,miR205 ,mucoepidermoid carcinoma ,ACTIVATION ,miR22 ,MECT1-MAML2 FUSION TRANSCRIPT ,METASTASIS ,head and neck cancer ,ODONTOGENIC CYSTS ,transcriptomic analysis - Abstract
Publisher Copyright: Copyright © 2022 Naakka, Barros-Filho, Adnan-Awad, Al-Samadi, Marchi, Kuasne, Korelin, Suleymanova, Brown, Scapulatempo-Neto, Lourenço, Castilho, Kowalski, Mäkitie, Araújo, Leivo, Rogatto, Salo and Passador-Santos. Objectives: To integrate mRNA and miRNA expression profiles of mucoepidermoid carcinomas (MECs) and normal salivary gland (NSGs) tissue samples and identify potential drivers. Material and Methods: Gene and miRNA expression arrays were performed in 35 MECs and six NSGs. Results: We found 46 differentially expressed (DE) miRNAs and 3,162 DE mRNAs. Supervised hierarchical clustering analysis of the DE transcripts revealed two clusters in both miRNA and mRNA profiles, which distinguished MEC from NSG samples. The integrative miRNA-mRNA analysis revealed a network comprising 696 negatively correlated interactions (44 miRNAs and 444 mRNAs) involving cell signaling, cell cycle, and cancer-related pathways. Increased expression levels of miR-205-5p and miR-224-5p and decreased expression levels of miR-139-3p, miR-145-3p, miR-148a-3p, miR-186-5p, miR-338-3p, miR-363-3p, and miR-4324 were significantly related to worse overall survival in MEC patients. Two overexpressed miRNAs in MEC (miR-22 and miR-205) were selected for inhibition by the CRISPR-Cas9 method. Cell viability, migration, and invasion assays were performed using an intermediate grade MEC cell line. Knockout of miR-205 reduced cell viability and enhanced ZEB2 expression, while miR-22 knockout reduced cell migration and invasion and enhanced ESR1 expression. Our results indicate a distinct transcriptomic profile of MEC compared to NSG, and the integrative analysis highlighted miRNA-mRNA interactions involving cancer-related pathways, including PTEN and PI3K/AKT. Conclusion: The in vitro functional studies revealed that miR-22 and miR-205 deficiencies reduced the viability, migration, and invasion of the MEC cells suggesting they are potential oncogenic drivers in MEC.
- Published
- 2022
35. Incidence of head and neck cancer among first-generation immigrants and their children in Finland.
- Author
-
Mroueh, Rayan, Hirvonen, Elli, Pitkäniemi, Janne, Malila, Nea, Hagström, Jaana, Mäkitie, Antti, and Virtanen, Anni
- Subjects
EMIGRATION & immigration & psychology ,CONFIDENCE intervals ,HEAD & neck cancer ,DISEASE incidence ,RISK assessment ,COMPARATIVE studies ,RESEARCH funding ,PHARYNX tumors ,SMOKING ,DISEASE risk factors - Abstract
Limited data exist regarding head and neck cancer (HNC) burden among immigrants who may have distinct characteristics, and hence different incidence rates from the general population. Variations in behavioral habits, cultural lifestyle, or diet may cause variations across different subgroups. The whole immigrant population of Finnish residents born abroad, and their children were retrieved for the years 1970–2017. First-generation immigrants are defined as individuals born abroad, excluding their children (even if born abroad). The study comprised 0.5 million first-generation immigrants and 0.3 million children, contributing to 6 million and 5 million person-years of follow-up, respectively. Standardized incidence ratios (SIR) and excess absolute risk (EAR) per 100,000 person-years at risk were calculated to quantify the risk of HNC among immigrants relative to the general Finnish population. The overall risk of any HNC was not increased among first-generation male immigrants (SIR 1.00, 95% CI: 0.88–1.15), but significantly elevated for cancer of the pharynx (SIR 1.56, 95% CI: 1.22–1.95), and larynx (SIR 1.38, 95% CI: 1.02–1.83) and decreased for lip (SIR 0.38, 95% CI: 0.20–0.67). The increased risk of pharyngeal cancer was highest among male immigrants from Asia Pacific (SIR 4.21, 95% CI: 2.02–7.75). First-generation immigrant women had a significantly reduced risk of any HNC (SIR 0.45, 95% CI: 0.37–0.55), which remained even after stratification by site. We observed no increased risk of any HNC among the children of first-generation immigrants. Healthcare professionals need to recognize the groups at higher HNC risk. Efforts to address the main etiological risk factors, such as smoking, are needed among the selected immigrant populations, that haven't yet reached similar decreasing trends, as in for example smoking, as the main population. Currently, globally, over 280 million people live outside their country of birth. Limited data exist regarding head and neck cancer (HNC) burden among immigrants who may have distinct characteristics and hence different incidence rates from the general population. Immigrant studies can provide novel data by shedding light on risk alterations and the pace of acculturation of different populations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Standardization for oncologic head and neck surgery
- Author
-
Ronen, O, Robbins, KT, de Bree, R, Guntinas-Lichius, O, Hartl, DM, Homma, A, Khafif, A, Kowalski, LP, Lopez, Fernando, Mäkitie, Antti A., Ng, WT, Rinaldo, A, Rodrigo, JP, Sanabria, A, Ferlito, A, HUS Head and Neck Center, Clinicum, and Korva-, nenä- ja kurkkutautien klinikka
- Subjects
MANDIBULAR RECONSTRUCTION ,QUALITY-ASSURANCE ,MULTIDISCIPLINARY CARE ,ILIAC CREST ,Standardization ,Quality assurance ,PATIENT SAFETY INDICATORS ,NCIC CTG ,HEALTH-CARE RESEARCH ,Surgical oncology ,WORKING COMMITTEE ,3125 Otorhinolaryngology, ophthalmology ,Head and neck cancer ,FREE-FLAP ,ORAL-CAVITY - Abstract
The inherent variability in performing specific surgical procedures for head and neck cancer remains a barrier for accurately assessing treatment outcomes, particularly in clinical trials. While non-surgical modalities for cancer therapeutics have evolved to become far more uniform, there remains the challenge to standardize surgery. The purpose of this review is to identify the barriers in achieving uniformity and to highlight efforts by surgical groups to standardize selected operations and nomenclature. While further improvements in standardization will remain a challenge, we must encourage surgical groups to focus on strategies that provide such a level.
- Published
- 2021
37. ANO1 Expression Orchestrates p27Kip1/MCL1-Mediated Signaling in Head and Neck Squamous Cell Carcinoma
- Author
-
Filippou, Artemis, Pehkonen, Henna, Karhemo, Piia-Riitta, Väänänen, Juho, Nieminen, Anni I., Klefström, Juha, Grénman, Reidar, Mäkitie, Antti A., Joensuu, Heikki, Monni, Outi, ATG - Applied Tumor Genomics, Research Programs Unit, Faculty of Medicine, Outi Monni / Principal Investigator, CAN-PRO - Translational Cancer Medicine Program, Medicum, HUS Head and Neck Center, Clinicum, Korva-, nenä- ja kurkkutautien klinikka, Heikki Joensuu / Principal Investigator, HUS Comprehensive Cancer Center, and Department of Oncology
- Subjects
p27Kip1 ,3122 Cancers ,Ani9-5f ,p27(Kip1) ,ANO1 ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,targeted therapy ,lcsh:RC254-282 ,AZD-5991 ,Article ,stomatognathic diseases ,MCL1 ,intrinsic apoptosis ,head and neck cancer ,cell cycle - Abstract
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that derive from the mucosal epithelium of the upper aerodigestive tract and present high mortality rate. Lack of efficient targeted-therapies and biomarkers towards patients’ stratification are caveats in the disease treatment. Anoctamin 1 (ANO1) gene is amplified in 30% of HNSCC cases. Evidence suggests involvement of ANO1 in proliferation, migration, and evasion of apoptosis, however, the exact mechanisms remain elusive. Aim of this study was to unravel the ANO1-dependent transcriptional programs and expand the existing knowledge of ANO1 contribution to oncogenesis and drug response in HNSCC. We cultured two HNSCC cell lines established from primary tumors harboring amplification and high expression of ANO1 in three-dimensional collagen. Differential expression analysis of ANO1-depleted HNSCC cells demonstrated downregulation of MCL1 and simultaneous upregulation of p27Kip1 expression. Suppressing ANO1 expression led to redistribution of p27Kip1 from the cytoplasm to the nucleus and associated with a cell cycle arrested phenotype. ANO1 silencing or pharmacological inhibition resulted in reduction of cell viability and ANO1 protein levels, as well as suppression of pro-survival BCL2 family proteins. Collectively, these data provide insights of ANO1 involvement in HNSCC carcinogenesis and support the rationale that ANO1 is an actionable drug target.
- Published
- 2021
- Full Text
- View/download PDF
38. Management and outcome of salivary duct carcinoma in major salivary glands
- Author
-
Salovaara, Elina, Hakala, Olli, Bäck, Leif, Koivunen, Petri, Saarilahti, Kauko, Passador-Santos, Fabricio, Leivo, Ilmo, and Mäkitie, Antti A.
- Published
- 2013
- Full Text
- View/download PDF
39. Electronic Cigarettes and Head and Neck Cancer Risk-Current State of Art
- Author
-
Szukalska, Marta, Szyfter, Krzysztof, Florek, Ewa, Rodrigo, Juan P., Rinaldo, Alessandra, Mäkitie, Antti A., Strojan, Primoz, Takes, Robert P., Suarez, Carlos, Saba, Nabil F., Braakhuis, Boudewijn J. M., Ferlito, Alfio, HUS Head and Neck Center, Clinicum, Korva-, nenä- ja kurkkutautien klinikka, University of Helsinki, Helsinki University Hospital Area, Research Program in Systems Oncology, Research Programs Unit, and Faculty of Medicine
- Subjects
3122 Cancers ,GAS-CHROMATOGRAPHY ,toxicity ,AEROSOL ,MUCOSAL TISSUE ,head and neck squamous cell carcinoma ,carcinogenic compounds ,REPLACEMENT LIQUIDS ,FLUIDS ,electronic cigarettes ,NICOTINE ,head and neck cancer ,CYTOTOXICITY ,EXPOSURE ,SYSTEM ,SMOKERS - Abstract
Simple Summary The risk of developing cancer is always higher for tobacco smokers than for non-smokers. Electronic cigarettes (e-cigarettes) have become increasingly popular in the last decade and are considered less harmful than traditional tobacco products, due to the lower content of toxic and carcinogenic compounds. However, this is still a controversial issue. This paper contains a review of previous reports on the composition of e-cigarettes and their impact on the pathogenesis and risk of head and neck cancer (HNC). The authors reviewed articles on both toxic and carcinogenic compounds contained in e-cigarettes and their molecular and health effects on the upper respiratory tract in comparison to traditional tobacco cigarettes. In conclusion, the studies discussed in the review strongly suggest that more long-term studies are needed to better address the safety of e-cigarettes. E-cigarettes have become increasingly popular in the last decade and are considered less harmful than traditional tobacco products due to the lower content of toxic and carcinogenic compounds. However, this is still a controversial issue. This paper contains a review of previous reports on the composition of e-cigarettes and their impact on the pathogenesis and risk of head and neck cancer (HNC). The objective of the review was to compare the molecular and health effects of e-cigarette use in relation to the effects of traditional cigarette smoking in the upper respiratory tract, and to assess the safety and effect of e-cigarettes on HNC risk. A review for English language articles published until 31 August 2020 was made, using a PubMed (including MEDLINE), CINAHL Plus, Embase, Cochrane Library and Web of Science data. The authors reviewed articles on both toxic and carcinogenic compounds contained in e-cigarettes and their molecular and health effects on the upper respiratory tract in comparison to tobacco cigarettes. The risk of developing head and neck squamous cell carcinoma (HNSCC) remains lower in users of e-cigarettes compared with tobacco smokers. However, more long-term studies are needed to better address the safety of e-cigarettes.
- Published
- 2020
40. Measureme-50nt of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty.
- Author
-
de Bree, Remco, Meerkerk, Christiaan D. A., Halmos, Gyorgy B., Mäkitie, Antti A., Homma, Akihiro, Rodrigo, Juan P., López, Fernando, Takes, Robert P., Vermorken, Jan B., and Ferlito, Alfio
- Subjects
HEAD & neck cancer ,SARCOPENIA ,FRAILTY ,CANCER patients ,MUSCLE mass ,CERVICAL vertebrae - Abstract
In head and neck cancer (HNC) there is a need for more personalized treatment based on risk assessment for treatment related adverse events (i.e. toxicities and complications), expected survival and quality of life. Sarcopenia, defined as a condition characterized by loss of skeletal muscle mass and function, can predict adverse outcomes in HNC patients. A review of the literature on the measurement of sarcopenia in head and neck cancer patients and its association with frailty was performed. Skeletal muscle mass (SMM) measurement only is often used to determine if sarcopenia is present or not. SMM is most often assessed by measuring skeletal muscle cross-sectional area on CT or MRI at the level of the third lumbar vertebra. As abdominal scans are not always available in HNC patients, measurement of SMM at the third cervical vertebra has been developed and is frequently used. Frailty is often defined as an age-related cumulative decline across multiple physiologic systems, with impaired homeostatic reserve and a reduced capacity of the organism to withstand stress, leading to increased risk of adverse health outcomes. There is no international standard measure of frailty and there are multiple measures of frailty. Both sarcopenia and frailty can predict adverse outcomes and can be used to identify vulnerable patients, select treatment options, adjust treatments, improve patient counselling, improve preoperative nutritional status and anticipate early on complications, length of hospital stay and discharge. Depending on the definitions used for sarcopenia and frailty, there is more or less overlap between both conditions. However, it has yet to be determined if sarcopenia and frailty can be used interchangeably or that they have additional value and should be used in combination to optimize individualized treatment in HNC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Exhaled breath analysis in the diagnosis of head and neck cancer
- Author
-
Mäkitie, Antti A., Almangush, Alhadi, Youssef, Omar, Metsälä, Markus, Silen, Suvi, Nixon, Iain J., Haigentz, Missak, Rodrigo, Juan P., Saba, Nabil F., Vander Poorten, Vincent, Ferlito, Alfio, HUS Head and Neck Center, Department of Ophthalmology and Otorhinolaryngology, Research Program in Systems Oncology, Research Programs Unit, University of Helsinki, Oral and Maxillofacial Surgery, Department of Pathology, Faculty of Medicine, Medicum, Department of Chemistry, and Clinicum
- Subjects
HPV ,diagnosis ,BIOMARKERS ,exhaled breath analysis ,VOLATILE ORGANIC-COMPOUNDS ,CONDENSATE PH ,3126 Surgery, anesthesiology, intensive care, radiology ,DISEASE ,MARKERS ,head and neck cancer ,SQUAMOUS-CELL CARCINOMA ,3125 Otorhinolaryngology, ophthalmology ,CONSTITUENTS ,COLLECTION - Abstract
Head and neck cancer (HNC) comprises a heterogeneous group of upper aerodigestive tract malignant neoplasms, the most frequent of which is squamous cell carcinoma. HNC forms the eighth most common cancer type and the incidence is increasing. However, survival has improved only moderately during the past decades. Currently, early diagnosis remains the mainstay for improving treatment outcomes in this patient population. Unfortunately, screening methods to allow early detection of HNC are not yet established. Therefore, many cases are still diagnosed at advanced stage, compromising outcomes. Exhaled breath analysis (EBA) is a diagnostic tool that has been recently introduced for many cancers. Breath analysis is non-invasive, cost-effective, time-saving, and can potentially be applied for cancer screening. Here, we provide a summary of the accumulated evidence on the feasibility of EBA in the diagnosis of HNC.
- Published
- 2020
42. Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
- Author
-
Almangush, Alhadi, Mäkitie, Antti A., and Leivo, Ilmo
- Subjects
- *
HEAD & neck cancer , *TUMOR-infiltrating immune cells - Published
- 2024
- Full Text
- View/download PDF
43. An analysis of dose response and survival
- Author
-
Koivunoro, Hanna, Kankaanranta, Leena, Seppälä, Tiina, Haapaniemi, Aaro, Mäkitie, Antti, Joensuu, Heikki, University of Helsinki, Sauli Savolainen / Principal Investigator, University of Helsinki, Department of Oncology, University of Helsinki, Department of Surgery, University of Helsinki, Department of Ophthalmology and Otorhinolaryngology, and University of Helsinki, Heikki Joensuu / Principal Investigator
- Subjects
Boron neutron capture therapy ,Radiotherapy ,Boronophenylalanine ,3122 Cancers ,Head and neck cancer - Abstract
Background and purpose: Head and neck squamous cell carcinoma (HNSCC) that recurs locally is a therapeutic challenge. We investigated the efficacy of boron neutron capture therapy (BNCT) in the treatment of such patients and the factors associated with treatment response and survival. Methods and materials: Seventy-nine patients with inoperable, locally recurred HNSCC were treated with l-boronophenylalanine-mediated BNCT in Espoo, Finland, between February, 2003 and January, 2012. Prior treatments consisted of surgery and conventionally fractionated radiotherapy to a median cumulative dose of 66 Gy (interquartile range [IQR], 59–70 Gy) administered with or without concomitant chemotherapy. Tumor response was assessed using the RECISTv.1.0 criteria. Results: Forty patients received BNCT once (on 1 day), and 39 twice. The median time between the 2 treatments was 6 weeks. Forty-seven (68%; 95% confidence interval [CI], 57–79%) of the 69 evaluable patients responded; 25 (36%) had a complete response, 22 (32%) a partial response, 17 (25%) a stable disease lasting for a median of 4.2 months, and 5 (7%) progressed. The patients treated with BNCT twice responded more often than those treated once. The median follow-up time after BNCT was 7.8 years. The 2-year locoregional progression-free survival rate was 38% and the overall survival rate 21%. A high minimum tumor dose and a small volume were independently associated with long survival in a multivariable analysis. Conclusions: Most patients responded to BNCT. A high minimum tumor dose from BNCT was predictive for response and survival.
- Published
- 2019
44. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature
- Author
-
Bossi, Paolo, Alfieri, Salvatore, Strojan, Primoz, Takes, Robert P., Lopez, Fernando, Mäkitie, Antti, Saba, Nabil F., Pablo Rodrigo, Juan, Bradford, Carol, Suarez, Carlos, Zafereo, Mark, Forastiere, Arlene A., Vermorken, Jan B., Quer, Miquel, Sanabria, Alvaro, Simo, Ricard, de Bree, Remco, Rinaldo, Alessandra, Ferlito, Alfio, Department of Ophthalmology and Otorhinolaryngology, Clinicum, HUS Head and Neck Center, and University of Helsinki
- Subjects
OUTCOMES ,Prognostic and predictive factors ,Recurrent and/or metastatic disease ,3122 Cancers ,SALVAGE SURGERY ,CETUXIMAB ,SURGICAL SALVAGE ,CANCER-ASSOCIATED HYPERCALCEMIA ,RADIATION-THERAPY ,SURVIVAL ,FAILURE ,Head and neck cancer ,HPV STATUS ,REIRRADIATION - Abstract
The pattern of clinical behaviour and response to treatment of recurrent and/or metastatic head and neck squamous cell carcinoma is heterogeneous. Treatment strategies that can be employed vary from potentially curative salvage surgery and re-irradiation to palliative systemic therapies and best supportive care. The advent of new therapeutic options, in terms of more sophisticated surgical approaches and techniques, highly conformal and precise radiation techniques and immunotherapy may offer improved control of disease and longer survival. Moreover, the epidemiological changes during the last decades, including the increase of human papilloma virus-related oropharyngeal primary tumors, are also reflected in the recurrent and metastatic setting. In this complex context the identification of predictive and prognostic factors is urgently needed to tailor treatment, to increase its efficacy, and to avoid unnecessary toxicities. A better knowledge of prognosis may also help the patients and caregivers in decision making on the optimal choice of care. The purpose of our review is to highlight the current evidence and shortcomings in this field.
- Published
- 2019
45. Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck.
- Author
-
Nuyts, Sandra, Bollen, Heleen, Eisbruch, Avrahram, Corry, June, Strojan, Primoz, Mäkitie, Antti A., Langendijk, Johannes A., Mendenhall, William M., Smee, Robert, DeBree, Remco, Lee, Anne W. M., Rinaldo, Alessandra, and Ferlito, Alfio
- Subjects
SQUAMOUS cell carcinoma ,HEAD & neck cancer ,IRRADIATION ,SUBMANDIBULAR gland ,NECK ,PAROTID glands - Abstract
Cancers of the head and neck region often present with nodal involvement. There is a long‐standing convention within the community of head and neck radiation oncology to irradiate both sides of the neck electively in almost all cases to include both macroscopic and microscopic disease extension (so called elective nodal volume). International guidelines for the selection and delineation of the elective lymph nodes were published in the early 2000s and were updated recently. However, diagnostic imaging techniques have improved the accuracy and reliability of nodal staging and as a result, small metastases that used to remain undetected and were thus in the past included in the elective nodal volume, will now be included in high‐dose volumes. Furthermore, the elective nodal areas are situated close to the parotid glands, the submandibular glands and the swallowing muscles. Therefore, irradiation of a smaller, more selected volume of the elective nodes could reduce treatment‐related toxicity. Several researchers consider the current bilateral elective neck irradiation strategies an overtreatment and show growing interest in a unilateral nodal irradiation in selected patients. The aim of this article is to give an overview of the current evidence about the indications and benefits of unilateral nodal irradiation and the use of SPECT/CT‐guided nodal irradiation in squamous cell carcinomas of the head and neck. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Familial cancer risk in family members and spouses of patients with early‐onset head and neck cancer.
- Author
-
Mroueh, Rayan, Tanskanen, Tomas, Haapaniemi, Aaro, Salo, Tuula, Malila, Nea, Mäkitie, Antti, and Pitkäniemi, Janne
- Subjects
HEAD & neck cancer ,FAMILY history (Medicine) ,CANCER ,SPOUSES - Abstract
Background Reported patterns of familial aggregation of head and neck cancer (HNC) vary greatly, with many studies hampered by the limited number of subjects. Methods: Altogether 923 early‐onset (≤40 years old) HNC probands, their first‐degree relatives, spouses, and siblings' offspring were ascertained. Cumulative risk and standardized incidence ratios (SIRs) were estimated. Results: Of all early‐onset HNC families, only 21 (2.3%) had familial HNC cancers at any age and less than five familial early onset HNC cancers among first‐degree relatives. The cumulative risk of HNC for siblings by age 60 (0.52%) was at population level (0.33%). No increased familial risk of early‐onset HNC could be discerned in family members (SIR 2.68, 95% CI 0.32‐9.68 for first‐degree relatives). Conclusions: Our study indicates that the cumulative and relative familial risk of early‐onset HNC is modest in the Finnish population and, at most, only a minor proportion of early‐onset HNCs are due solely to inherited genetic mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. Risk of second primary cancer in oral squamous cell carcinoma.
- Author
-
Mroueh, Rayan, Nevala, Aapeli, Haapaniemi, Aaro, Pitkäniemi, Janne, Salo, Tuula, and Mäkitie, Antti A.
- Subjects
SQUAMOUS cell carcinoma ,MEDICAL personnel ,SECONDARY primary cancer ,HEAD & neck cancer - Abstract
Background: The incidence and survival of oral squamous cell carcinoma (OSCC) patients have increased in recent years. Understanding their long‐term survival aspects is essential for optimal treatment and follow‐up planning. Almost one in five cancers diagnosed occurs nowadays in individuals with a previous diagnosis of cancer. Methods: Patients diagnosed with primary OSCC during 1953‐2015 were retrieved from the Finnish Cancer Registry. Both standardized incidence ratios (SIR) and excess absolute risk (EAR) per 1000 person‐years at risk (PYR) of second primary cancer (SPC) were calculated relative to the general population. Results: Among 6602 first primary OSCC patients there were 640 (10%) SPCs. The SIR for SPCs was 1.85 (95% CI: 1.71‐1.99, P <.001) corresponding to an EAR of 8.78 (95% CI: 7.29‐10.26). Conclusions: Health care professionals should be aware of the second primary cancer risk after management of primary OSCC and patients need to be counseled about this phenomenon. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
48. The risk of second primary tumors in head and neck cancer: A systematic review.
- Author
-
Coca‐Pelaz, Andrés, Rodrigo, Juan P., Suárez, Carlos, Nixon, Iain J., Mäkitie, Antti, Sanabria, Alvaro, Quer, Miquel, Strojan, Primož, Bradford, Carol R., Kowalski, Luiz P., Shaha, Ashok R., Bree, Remco, Hartl, Dana M., Rinaldo, Alessandra, Takes, Robert P., and Ferlito, Alfio
- Subjects
SECONDARY primary cancer ,HEAD & neck cancer ,META-analysis ,HEAD tumors ,LIFE expectancy - Abstract
Background: Second primary tumors (SPTs) are a common cause of reduced life expectancy in patients treated for head and neck cancer (HNC). This phenomenon forms an area to be addressed during posttreatment follow‐up. Methods: We conducted a systematic review of literature following PRISMA guidelines, from 1979 to 2019, to investigate incidence of SPTs, synchronous, and metachronous, in HNC population. Results: Our review includes data of 456 130 patients from 61 articles. With a minimum follow‐up of 22 months, mean incidence of SPTs was 13.2% (95% CI: 11.56‐14.84): 5.3% (95% CI: 4.24‐6.36) for synchronous SPTs and 9.4% (95% CI: 7.9‐10.9) for metachronous SPTs. The most frequent site for SPTs was head and neck area, followed by the lungs and esophagus. Conclusion: Although with wide variations between studies, the rate of SPTs in HNC patients is high. Given the impact in the prognosis, we must develop strategies for the early diagnosis of SPTs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
49. Body Composition Evaluation in Head and Neck Cancer Patients: A Review.
- Author
-
Almada-Correia, Inês, Neves, Pedro Miguel, Mäkitie, Antti, and Ravasco, Paula
- Subjects
BODY composition ,DUAL-energy X-ray absorptiometry ,BIOELECTRIC impedance ,MUSCLE mass ,CANCER patients ,HEAD & neck cancer - Abstract
Introduction: Head and neck cancer (HNC) patients show a high risk of malnutrition due to the lifestyle habits adopted prior to the diagnosis as well as to the compromising impact of both the anatomical location of the tumor and the treatment modalities on food intake. Weight change, measurement of skinfold thickness, biochemical parameters, bioelectrical impedance analysis (BIA), computed tomography (CT), magnetic resonance (MRI), or dual-energy x-ray absorptiometry (DXA) are available techniques to evaluate nutritional status and/or body composition in the clinical practice. Evaluating body composition alterations in HNC patients is essential to be able to offer the best therapeutical interventions. In this paper, we review the existing literature regarding body composition evaluation in HNC patients to determine, which is the most suitable method for this population, regarding availability in the day-to-day practice, patient burden, cost, sensibility, and specificity. Methodology: A literature search for relevant papers indexed in MEDLINE, Cochrane Library and Scielo was conducted, with no publication date restriction and for all published articles until the 31 January, 2019. All the papers written in English, with interventions in humans, exclusively considering HNC patients were selected. Results: A total of 41 studies with different methodologies were included in this review. In 15 studies BIA was the used assessment method and three of them also evaluated skinfold thickness and one was a bioelectric impedance vector analysis (BIVA). Body composition assessment was made with DXA in eight studies, one of which also included muscle biopsies. In two studies the chosen method was both BIA and DXA. CT/ positron emission tomography-CT was applied in 11 studies and one also included MRI. In two studies body composition was assessed with skinfold measurements alone and one study only used BIVA. Conclusions: Despite the different existing body composition assessment tools, it seems that skeletal muscle mass (SMM) measurement at the level of cervical spine C3 vertebra may be a reliable method for SMM assessment as it strongly correlates with cross-sectional area measures at the level of L3 and it allows a cost-effective body composition assessment without the need for additional radiation exposure. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
50. An evaluation of the diagnostic methods in head and neck cancer of unknown primary site.
- Author
-
Aro, Katri, Bäck, Leif, Tapiovaar, Laura, and Mäkitie, Antti
- Subjects
ACADEMIC medical centers ,COMPUTED tomography ,PAP test ,HEAD tumors ,SURVIVAL ,NECK tumors ,POSITRON emission tomography ,DISEASE incidence ,CANCER of unknown primary origin ,RETROSPECTIVE studies ,EARLY detection of cancer ,OROPHARYNGEAL cancer ,DIAGNOSIS ,CANCER treatment ,PROGNOSIS ,TUMOR treatment - Abstract
Background: Various detection methods to identify the primary in head and neck cancer of unknown primary (HN-CUP) require evaluation to improve and standardize management. Objectives: To evaluate the use of different diagnostic methods, which aim at decreasing the incidence of HN-CUP. Material and methods: We conducted a retrospective analysis of patients with HN-CUP at the Helsinki University Hospital during 1995-2011. We evaluated clinical assessment, definitive treatment, histopathology, and follow up. We analyzed the success in identifying the primary site to show any changes in diagnostic methods over time. Results: Frequency of HN-CUP and success in identifying the primary site have remained constant despite the addition of PET-CT and determination of human papilloma virus (HPV) status in diagnostics. Among 133 patients, the diagnostic work up identified the primary site in 53% and the oropharynx predominated (69%). This left 85 patients with HN-CUP and 5-year overall and disease-free survival rates were 71 and 69%, respectively. Conclusions: Panendoscopy including tonsillectomy should not be omitted in the work up. Significance: We demonstrate a steady frequency of HN-CUP and constant success in identifying the primary site. Detection of a primary later in the follow up did not impact the survival. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.